Vaccine Contender CureVac Raises $213 Million in IPO

(Bloomberg) -- CureVac BV, a competitor in the race for a coronavirus vaccine, priced its U.S. initial public offering at the top of a marketed range to raise $213 million.
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.